Toyota's American depositary shares are in the high 70s -- down nearly 50% from two years ago. If the auto market perks up, they can hit at least 115 during the next year.

Hanover's depressed shares could surge nearly 30%, as the company reaps the rewards of a tighter strategic focus, a strong balance sheet and investment in technology.

Range's stock, beaten down in recent months, could climb 30% as natural gas prices rise. And if the company succeeds in the Marcellus Shale, the shares could soar for years.

A sea change toward mail order and generic drugs also should help CVS in the long run. Meanwhile, a recent program called "Maintenance Choice" that lets customers pick up 90-day prescriptions at drugstores is winning converts and boosting foot traffic at its thousands of retail stores. CVS has had to cut prices to keep clients in but the worst re-pricing is behind. With nearly $9 billion in recent contract wins, Canaccord analyst Simeon Gutman thinks CVS "is on the cusp of an inflection point," with drug-benefit management poised to boost performance over the next 12 months. Even management recognizes that shares are cheap, and is buying back $2 billion worth of shares.

Take Teva Pharmaceutical (TEVA), which makes generic and branded drugs and has some 200 applications for new generic treatments before the FDA. Shares are up 14% this year, and it's widely assumed that healthcare reform will benefit generic drugs. But Goldman Sachs analyst Randall Stanicky flags other catalysts that could drive shares higher. For instance, generic Adderall XR, Pulmicort and Allegra D could boost second-half earnings, and synergies from its $7.4 billion purchase of Barr Pharmaceuticals late last year should become more apparent soon. A weaker dollar also should help the Israeli company.

In comparison, proposed reform that curbs drug costs and paves the way for cheaper copies will pressure Genzyme (GENZ), which earns half its revenue within the U.S. Genzyme also derives a quarter of its sales from Cerezyme, which treats a rare disorder called Gaucher disease. But competitors including Shire (SHPGY) and Protalix BioTherapeutics (PLX) are developing rival treatments and should unveil trial data in the coming months. As such, investors willing to relinquish potential upside in Genzyme might sell January call options on the stock and use the proceeds to buy January calls on Teva, suggests Goldman's option strategist John Marshall. That essentially harnesses calls on health-care-reform losers to fund call purchases on likely reform winners. Genzyme shares were trading recently for 13 times projected 2010 profits, while Teva's American depositary receipts were fetching 11.4 times.

Experts in the carbon sector say investors have plenty of ways to capitalize on the current favorable winds, as more companies become involved in the process of reducing emissions or trading credits. One such firm is World Energy Solutions (XWES), which helps with the administration of the RGGI auctions. Company executives say the prospect of a national cap-and-trade program could be an enormous opportunity for their business or a similar firm. . Other options include emissions-related contracts currently offered by Chicago Climate Exchange, owned by Climate Exchange (CLE.U.K.); the Green Exchange, owned by CME Group (CME); and Europe's BlueNext, to name a few.

Experts in the carbon sector say investors have plenty of ways to capitalize on the current favorable winds, as more companies become involved in the process of reducing emissions or trading credits. One such firm is World Energy Solutions (XWES), which helps with the administration of the RGGI auctions. Company executives say the prospect of a national cap-and-trade program could be an enormous opportunity for their business or a similar firm. . Other options include emissions-related contracts currently offered by Chicago Climate Exchange, owned by Climate Exchange (CLE.U.K.); the Green Exchange, owned by CME Group (CME); and Europe's BlueNext, to name a few.